Integrated Advisors Network LLC Sells 8,536 Shares of Novo Nordisk A/S (NYSE:NVO)

Integrated Advisors Network LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 69.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,791 shares of the company's stock after selling 8,536 shares during the period. Integrated Advisors Network LLC's holdings in Novo Nordisk A/S were worth $326,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Victory Capital Management Inc. raised its stake in shares of Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after acquiring an additional 23,223 shares during the last quarter. Bryn Mawr Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 358.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after acquiring an additional 30,420 shares during the last quarter. Clear Creek Financial Management LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $450,000. DSM Capital Partners LLC raised its position in Novo Nordisk A/S by 16.7% during the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock valued at $172,678,000 after purchasing an additional 286,912 shares during the last quarter. Finally, Channing Global Advisors LLC bought a new position in Novo Nordisk A/S during the 4th quarter valued at approximately $354,000. Institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on NVO. BMO Capital Markets restated a "market perform" rating and set a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $128.00.

Novo Nordisk A/S Stock Up 2.8%

NVO traded up $1.94 during trading on Friday, reaching $71.40. The stock had a trading volume of 11,185,051 shares, compared to its average volume of 6,800,832. The stock's 50 day moving average is $65.58 and its two-hundred day moving average is $81.59. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $320.41 billion, a price-to-earnings ratio of 21.70, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.